RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Icagen, Inc. (NASDAQ: ICGN) today provided an update on its research programs focused on sodium channels including the sodium channel target SCN9A for the treatment of chronic pain. Sodium channels like SCN9A, also called PN1 or Nav1.7, are promising ion channel targets, which the Company is pursuing for the treatment of chronic pain.
